CVS to Pay $315 Million to Settle DOJ Opioid Prescription Case

CVS Pharmacy Inc. and its affiliated corporate entities will pay $315 million to resolve a Justice Department civil case alleging that the company illegally filled prescriptions for opioids and other controlled substances for more than a decade and then sought payment for many of them from Medicare and other federal health programs. The settlement, announced Tuesday, covers alleged conduct from Oct. 17, 2013, through Dec. 2, 2025.

The government's complaint, filed Dec. 13, 2024, in the U.S. District Court for the District of Rhode Island, accused the Rhode Island-based chain of dispensing controlled substances that lacked a legitimate medical purpose and of billing federal health programs for the resulting claims — violations of the Controlled Substances Act and the False Claims Act. "Not only does this settlement hold bad actors accountable for their fraudulent activities, but Americans are safer because of it," Associate Attorney General Stanley E. Woodward Jr. said in a statement announcing the agreement.

What the government says CVS filled

Federal lawyers alleged that CVS dispensed dangerous and excessive quantities of opioids, filled opioid prescriptions too early, and processed so-called trinity prescriptions — a combination of an opioid, a benzodiazepine and a muscle relaxant that the department describes as dangerous and widely abused. The complaint also says the chain filled prescriptions written by "pill mill" prescribers who issued large numbers of controlled-substance prescriptions without a medical purpose, and that its pharmacists did so despite red flags indicating the prescriptions were not valid.

Prosecutors tied the alleged violations to the company's own operations. They said corporate-imposed performance metrics, incentive compensation and staffing policies prioritized profits over patient safety, that CVS failed to employ enough pharmacists to meet both its legal obligations and its internal targets, and that its policies prevented pharmacists from warning one another about certain problematic prescribers. Many of the prescriptions at issue were ultimately reimbursed by federal health care programs, according to the department.

The safeguards CVS has agreed to adopt

Beyond the payment, CVS entered a memorandum of agreement with the Drug Enforcement Administration that governs how it dispenses controlled substances going forward. Under the agreement, the company must set up a hotline for employees and the public to report suspected illegal dispensing, proactively monitor dispensing patterns across its pharmacies to identify and address potentially unlawful activity, and create a process for evaluating prescribers suspected of illegal prescribing.

"Today's settlement requires CVS to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate," said Assistant Attorney General Brett A. Shumate, who leads the department's Civil Division. "The remedial measures in this agreement — including proactive monitoring of opioid prescribing patterns — will provide critical protections for patients and federal healthcare programs."

DEA Assistant Administrator Cheri Oz said the deal reflects the agency's intent to hold pharmacies to "the highest standards of responsible dispensing." Charles C. Calenda, First Assistant U.S. Attorney for the District of Rhode Island, said pharmacies "must maintain effective compliance systems to identify and respond to warning signs that prescriptions may be unlawful or medically unnecessary."

A whistleblower, a denial and a long-running dispute

The civil settlement resolves a whistleblower lawsuit brought by Hillary Estright, a former CVS employee, the department said.

CVS disputed the government's account. The company said its pharmacists were trained "in the safe and appropriate use of all medications" and that it had implemented what it called best-in-class programs to help them make decisions on behalf of patients. It said it strongly disagreed with the claims and that the settlement admits no wrongdoing. When the suit was filed in 2024, the company argued that pharmacists were being held to "vague, undefined, and ever-changing standards of practice" when filling opioid prescriptions.

One deal in a decade of settlements

The $315 million is far smaller than the multibillion-dollar agreements pharmacy chains reached with state and local governments, but it is a federal enforcement action rather than a distribution of state settlement funds. Over the past decade, drugmakers, wholesalers, pharmacies and other companies have agreed to settlements with U.S. governments totaling more than $50 billion, most of it intended to address the addiction and overdose crisis. Most of that money has come through deals with state and local governments, though the federal government has reached several of its own, including with the pharmacies Walgreens and Walmart over the past two years.

Fatal overdoses have fallen sharply in recent years after being linked to more than 100,000 deaths in some years, but illicit fentanyl and other potent synthetic opioids remain the leading driver of overdose deaths. People seeking care for opioid use disorder can find medication-assisted treatment nationwide, and naloxone reverses opioid overdoses and is now sold over the counter.